Clinical implications of extracellular vesicles in neurodegenerative diseases
Abstract
Introduction: Extracellular vesicles (EVs) released by neural cells play a crucial role in intracellular communication in both physiological and pathological states. Recent studies have shown that the neuropathogenic manifestation of many progressive nervous system diseases including Parkinson’s disease (PD), Alzheimer’s diseases (AD), and amyotrophic lateral sclerosis (ALS). These diseases are frequently found to be associated with the accumulation of misfolded proteins, exploit EVs for the spread of aggregates to naive cells in a prion-like mechanism. Therefore, characterization of EVs and understanding their mechanism of action could open a window of opportunity to discover biomarkers and therapeutic targets in a disease-specific manner.Areas covered: In this review, we discuss the role of neural cells-derived EVs in normal and disease states. We also highlight their biomedical potential in modern medicine, including the use of circulating EVs as biomarkers for diagnosis with a special focus on newly-identified potential biomarkers in neurodegenerative disease, and novel methodologies in EVs isolation.Expert opinion: Systematic and comprehensive analysis of EVs in different biofluid sources is needed. Considering the potential for tremendous clinical benefits of EVs research in neurodegenerative disease, there is also an urgent need to standardize neural cells-derived EV enrichment protocols for consensus results.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Recent research has highlighted the significant role of sEVs in the propagation of misfolded proteins in neurodegenerative diseases, suggesting they may facilitate intercellular transfer and contribute to the progression and severity of these conditions.
“Recent research has highlighted the significant role of sEVs in the propagation of these misfolded proteins, suggesting they may facilitate intercellular transfer and contribute to the progression and severity of these conditions [130–132].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [132]
Cites
Self-propagation of pathogenic protein aggregates in neurodegenerative diseases
Jucker, M., & Walker, L. C. (2013) · Nature · doi:10.1038/nature12481 · Cited by 1,663 · see citing works
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590 · see citing works
Akers, J. C., Gonda, D., Kim, R., Carter, B. S., & Chen, C. C. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1084-8 · Cited by 1,423 · cited 1× · see citing works
“Although there are some discrepancies between literature with regard to nomenclature, EVs can be broadly sub-classified into microvesicles, exosomes, and apoptotic bodies [1].”
BackgroundHolmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · see citing works
Saman, S., Kim, W., Raya, M., Visnick, Y., Miro, S., Saman, S., Jackson, B., McKee, A. C., Alvarez, V. E., Lee, N. C. Y., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.277061 · Cited by 985 · see citing works
Fiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.008 · Cited by 959 · see citing works
Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds
Holmes, B. B., DeVos, S. L., Kfoury, N., Li, M., Jacks, R., Yanamandra, K., Ouidja, M. O., Brodsky, F. M., Marasa, J., Bagchi, D. P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301440110 · Cited by 859 · see citing works
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753 · see citing works
Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660 · see citing works
Fernando, M. S., Simpson, J. E., Matthews, F., Brayne, C., Lewis, C. E., Barber, R., Kalaria, R. N., Forster, G., Esteves, F., Wharton, S. B., et al. (2006) · Stroke · doi:10.1161/01.str.0000221308.94473.14 · Cited by 587 · see citing works
Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
Sardar Sinha, M., Ansell-Schultz, A., Civitelli, L., Hildesjö, C., Larsson, M., Lannfelt, L., Ingelsson, M., & Hallbeck, M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1868-1 · Cited by 527 · see citing works
Plasma β-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy
Gurol, M. E., Irizarry, M. C., Smith, E. E., Raju, S., Diaz-Arrastia, R., Bottiglieri, T., Rosand, J., Growdon, J. H., & Greenberg, S. M. (2006) · Neurology · doi:10.1212/01.wnl.0000191403.95453.6a · Cited by 339 · see citing works
Dickens, A. M., Tovar-y-Romo, L. B., Yoo, S.-W., Trout, A. L., Bae, M., Kanmogne, M., Megra, B., Williams, D. W., Witwer, K. W., Gacias, M., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aai7696 · Cited by 285 · see citing works
Proteostasis and the Aging Proteome in Health and Disease
Morimoto, R. I., & Cuervo, A. M. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glu049 · Cited by 277 · see citing works
Kester, M. I., Goos, J. D. C., Teunissen, C. E., Benedictus, M. R., Bouwman, F. H., Wattjes, M. P., Barkhof, F., Scheltens, P., & van der Flier, W. M. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.754 · Cited by 161 · see citing works
Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome
Hamlett, E. D., Goetzl, E. J., Ledreux, A., Vasilevko, V., Boger, H. A., LaRosa, A., Clark, D., Carroll, S. L., Carmona‐Iragui, M., Fortea, J., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.012 · Cited by 129 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions
Choi, H. K., Chen, M., Goldston, L. L., & Lee, K.-B. (2024) · Nano Convergence · doi:10.1186/s40580-024-00426-5 · Cited by 26 · see citing works
- Authors
- Vinaiphat, A., & Sze, S. K.
- Affiliations
- Nanyang Technological University (SG)
- Corresponding author
- Sze, Siu Kwan
- ORCID
- Sze, Siu Kwan
- Venue
- Expert Review of Molecular Diagnostics
- Publisher
- Informa UK Limited
- Published
- 2019-08-23
- Volume
- 19
- Issue
- 9
- Pages
- 813-824
- ISSN
- 1473-7159 (ISSN-L)
- 1744-8352
- OpenAlex
- W2969535702
- Cited by
- 20
- References
- 16
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 5 · 2020: 2 · 2019: 1
- FWCI
- 0.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Molecular Diagnostics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- extracellular vesicles, neurodegenerative diseases, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, prion-like propagation, protein aggregation, biomarkers, EV isolation, biological fluids, therapeutic target
- MeSH terms
- Neuroprotection, Extracellular Vesicles, Humans, Neurons, Prions, Biomarkers, Neurodegenerative Diseases, Exosomes, Proteostasis Deficiencies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
